Article Text

Download PDFPDF

Response to: ‘Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’ by Comarmond et al
Free
  1. Alessandro Tomelleri1,2,
  2. Silvia Sartorelli1,
  3. Elena Marina Baldissera1,
  4. Lorenzo Dagna1,2,
  5. Corrado Campochiaro1,2
  1. 1Unit of Immunology, Rheumatology, Allergy and Rare diseases, San Raffaele Hospital, Milano, Lombardia, Italy
  2. 2Università Vita Salute San Raffaele, Milano, Lombardia, Italy
  1. Correspondence to Dr Corrado Campochiaro, Unit of Immunology, Rheumatology, Allergy and Rare diseases, San Raffaele Hospital, Milano, Lombardia, Italy; campochiaro.corrado{at}hsr.it

Statistics from Altmetric.com

We read with interest the correspondence by Comarmond et al1 on our study about the impact of novel COVID-19 on Italian patients with large-vessels vasculitis (LVV).2 COVID-19 has been declared a global pandemic by WHO in March 2020. Since then, the number of patients diagnosed with SARS-CoV-2 infection has rapidly grown and today more than 46 million cases worldwide have been identified.3

International and National surveys on different groups of patients with chronic inflammatory diseases have been performed to evaluate the impact of COVID-19 pandemic among frail patients.4 5 After a first study by our group, based in Milan, Italy,2 Comarmond et al reported the results of a survey conducted among patients affected by LVV, followed up at Pitié-Salpêtrière Hospital (Paris, France).1 Both studies were performed during the so-called ‘first wave’ of the pandemic, in areas characterised by a high rate of infection, and among patients followed up in tertiary referral centres. In addition, the number of patients included and the ratio between patients affected by the two main LVVs (ie, Giant cell arteritis and Takayasu’s arteritis) were similar. Nonetheless, some of the results obtained seem controversial.

In our cohort of LVV patients, we detected a low rate of SARS-CoV-2 infection (2.5%), with no related deaths, whereas the infection rate reported by Comarmond et al was double (5.4%) and associated with a lethality of 12.5%. The French authors suggested that a higher use of tocilizumab in our cohort (33% vs 10%) might be accounted for the difference in the observed outcome. However, a few elements should be pointed out when comparing the two cohorts.

First, while we included only LVV-COVID-19+ patients diagnosed by means of reverse transcription CR (RT-PCR), the standard recommended confirmatory test,6 in only two of the eight patients reported by the French authors a positive RT-PCR was identified.

Second, the French survey was conducted 1 month after ours and evaluated a time span including not only March but also April. This difference has two main consequences. Intuitively, a longer period of observation implies a higher probability of finding new cases. In addition, in March the availability of RT-PCR tests was extremely limited in Italy and, since we aimed at identifying only RT-PCR positive COVID-19 cases, this might have reduced the number of patients correctly diagnosed.

Third, the lethality rate described by Comarmond et al is a consequence of the death of a single 57-year-old patient affected by Takayasu’s arteritis. However, it should be underlined the fact that the past medical history of this patient was characterised by a large number of comorbidities (eg, arterial hypertension, diabetes, cardiovascular disease and B lymphoma), some of them not directly related to the primary diagnosis. As a consequence, it is quite hard to properly estimate the influence of each of these factors on the final outcome.

The last point refers to the impact of the interleukin-6 receptor antagonist tocilizumab on the outcome of LVV patients. The French authors correctly pointed out that one patient out of three from our cohort was treated with tocilizumab at the time covered by the survey, a fraction considerably higher than that reported by their group (10%). This observation led them to hypothesise a positive influence of this therapy on the disease course. However, none of the four LVV patients with COVID-19 from our study was concurrently treated with tocilizumab. Moreover, three recently published randomised controlled trials failed to show clear evidence of efficacy of tocilizumab in the management of COVID-19 patients outside the intensive care unit.7–9 Conversely, both the patients affected by Takayasu’s arteritis diagnosed with SARS-CoV-2 infection included in our survey were concomitantly on anti-tumor necrosis factor (TNF)α drugs. The potential beneficial effect of this family of drugs on the outcome of COVID-19 patients cannot be inferred by an observational study like ours, but it is already under evaluation in a prospective controlled trial (ie, ISRCTN33260034).

Multicentre International surveys on LVV patients are eagerly warranted to properly understand the outcome of COVID-19 in this subset of patients.

References

Footnotes

  • Handling editor Josef S Smolen

  • Contributors All authors contributed to the design of the work, acquisition, analysis and interpretation of data. All authors revised the work critically for important intellectual content and approved the final version of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles